Red Queen Therapeutics

Focus: Red Queen Therapeutics is a Cambridge-based biotech company focused on developing fusion inhibitors to prevent and treat viral infections, particularly in infectious diseases.

Infectious Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About Red Queen Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Red Queen Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year P

HIV Infection

N/A

Clinical Trials (1)

NCT01634477Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year Prospective Cohort Study

N/A

Help build intelligence for Red Queen Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage focus on fusion inhibitor platform with multiple infectious disease targets (COVID-19, HIV) offering scientific novelty
Phase 1 and Phase 3 programs provide exposure to both early-stage discovery and late-stage development workflows
Cambridge location provides access to major biotech talent pool and institutional networks

Watch Out For

Zero active job openings signal minimal near-term hiring or potential organizational stress
Data quality issues in pipeline (mixed trial designs, unclear drug names) suggest early-stage operational maturity concerns
No revenue, funding, employee count, or financial data available raises transparency and runway questions

Generated by Claude from Red Queen Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Hyperimmune intravenous immunoglobulin

Novel 2009 Influenza A (H1N1) Infection

N/A

Clinical Trials (1)

NCT01617317H-IVIG Treatment for Severe H1N1 2009

N/A

AZT/3TC 2 weeks after delivery

NVP Plasma Level

N/A

Clinical Trials (1)

NCT00872872Nevirapine Clearance After Short-term Highly Active Antiretroviral Therapy (HAART) for Prevention of Mother to Child Transmission of HIV (PMTCT)

N/A

Various interventions for each of the conditions.

Gastroschisis

N/A

Clinical Trials (1)

NCT03185637Children's Surgery in Sub-Saharan Africa

N/A

RQ-001

COVID-19

Phase 1

Clinical Trials (1)

NCT06063330Clinical Trial to Evaluate the Safety of RQ-01 in SARS-CoV-2 Positive Subjects

Phase 1

AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP

HIV Infections

Phase 3

Clinical Trials (1)

NCT00669487A 72-week Randomized Clinical Trial Comparing the Safety and Efficacy of Three Initial Antiretroviral Regimens -GPO-VIR S (d4T/3TC/NVP) for 24 Weeks Followed by GPO-VIR Z (AZT/3TC/NVP) vs GPO-VIR Z vs TDF/FTC/NVP

Phase 3